Jupiter Asset Management Ltd. Has $3.88 Million Stock Holdings in CareDx, Inc. $CDNA

Jupiter Asset Management Ltd. grew its position in shares of CareDx, Inc. (NASDAQ:CDNA) by 218.1% in the 2nd quarter, Holdings Channel reports. The firm owned 198,384 shares of the company’s stock after acquiring an additional 136,019 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in CareDx were worth $3,876,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. MCF Advisors LLC boosted its stake in CareDx by 292.9% during the second quarter. MCF Advisors LLC now owns 1,336 shares of the company’s stock worth $26,000 after acquiring an additional 996 shares in the last quarter. Allworth Financial LP purchased a new stake in CareDx in the 2nd quarter valued at $40,000. PNC Financial Services Group Inc. lifted its position in shares of CareDx by 20,200.0% during the first quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company’s stock valued at $79,000 after purchasing an additional 4,444 shares in the last quarter. Morse Asset Management Inc purchased a new position in shares of CareDx in the 1st quarter worth approximately $103,000. Finally, AlphaQuest LLC grew its stake in CareDx by 40.0% in the 2nd quarter. AlphaQuest LLC now owns 9,576 shares of the company’s stock valued at $187,000 after purchasing an additional 2,736 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on CDNA shares. Craig Hallum decreased their price target on shares of CareDx from $40.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, July 18th. BTIG Research raised their price target on shares of CareDx from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 6th. William Blair began coverage on shares of CareDx in a research note on Tuesday, August 26th. They issued a “market perform” rating on the stock. Weiss Ratings raised CareDx from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, November 7th. Finally, Wells Fargo & Company reduced their target price on shares of CareDx from $19.00 to $14.00 and set an “equal weight” rating on the stock in a report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $26.00.

CareDx Trading Down 2.7%

NASDAQ:CDNA opened at $15.87 on Friday. CareDx, Inc. has a 12 month low of $10.96 and a 12 month high of $26.37. The company has a 50-day moving average price of $14.78 and a 200-day moving average price of $15.55. The stock has a market cap of $816.24 million, a price-to-earnings ratio of 15.56 and a beta of 2.50.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.13 by $0.15. CareDx had a net margin of 17.97% and a return on equity of 18.03%. The company had revenue of $100.06 million for the quarter, compared to the consensus estimate of $95.25 million. During the same period in the prior year, the firm posted ($0.14) EPS. CareDx’s revenue for the quarter was up 20.7% on a year-over-year basis. CareDx has set its FY 2025 guidance at EPS. Equities analysts forecast that CareDx, Inc. will post -0.9 EPS for the current fiscal year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.